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with prediabetes or newly diagnosed diabetes:
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Abstract
Background: To examine whether elevated glycosylated hemoglobin A1c (HbA1c) is associated with hyperfiltration
in a middle-aged and elderly Chinese population.
Methods: Anthropometric and biochemical examinations were performed in 2491 individuals from the general
population, aged 40–79 years, who participated in the Huaian Diabetes Prevention Program. The estimated glomerular
filtration rate (eGFR) was calculated from creatinine levels using the CKD-EPI formula. Hyperfiltration was defined as
eGFR >90th percentile.
Results: After adjustment [for age, gender, waistline, body mass index, blood pressure, smoking, alcohol consumption,
cholesterol, log(triglycerides), high-density lipoprotein, low-density lipoprotein, serum uric acid, sodium intake,
hypertension, and use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers], HbA1c and fasting
plasma glucose (FPG) were found to be independently positively associated with eGFR. Additionally, after multivariate
adjustment, the odds ratios (95 % CI) for hyperfiltration calculated for a 1-unit increase in HbA1c and FPG were 1.396
(1.089–1.790) and 1.306 (1.117–1.526), respectively. Compared with participants with HbA1c levels <5.7 %, the odds
ratios (95 % CI) for hyperfiltration were 2.344 (1.025–5.364) in participants with HbA1c levels of 6.21–6.49 %, and
2.965 (1.537–5.720) in those with HbA1c levels ≥6.5 %.
Conclusion: Elevated HbA1c (≥6.21 %) is associated with an increased odds of hyperfiltration in middle-aged
and elderly Chinese. Longitudinal studies are needed to explore whether hyperfiltration increases the odds of
diabetic nephropathy in individuals with prediabetes.
Background
With the continuing increase in the number of patients
with diabetes mellitus, diabetic nephropathy (DN) has be-
come the most common cause of end-stage renal disease
(ESRD) in China [1], the USA [2], and Europe [3]. DN de-
velops in 40 % of patients with type 1 diabetes mellitus
(T1DM) [4] and in 25 % of patients with type 2 diabetes
mellitus (T2DM) [5]. Recent data from the Diabetes
Control and Complications Trial-Epidemiology of Dia-
betes Interventions and Complications (DCCT-EDIC)
study suggested that blood glucose levels at the time of
the measurement of estimated glomerular filtration rate
(eGFR) may bias the results [6]. Indeed, in patients with
T1DM, the risk of impaired eGFR was lower for those
treated early and aggressively compared with those with
conventional treatments [6]. Thus, early diagnosis of DN
and early intervention are very important.
Glycosylated hemoglobin (HbAlc) is widely accepted as
being a good indicator of blood glucose control. In 2010,
the American Diabetes Association (ADA) recommended
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that a HbAlc of 6.5 % or higher be used for the diagnosis
of diabetes mellitus [7]. In 2012, the ADA further recom-
mended an HbAlc of 5.7–6.4 % as a screening criterion
for individuals with high risk for future diabetes (prediabe-
tes) [8]. A community-based study has suggested that
baseline HbA1c is a stronger predictor of subsequent dia-
betes and cardiovascular events than fasting glucose [9].
However, very few studies have focused on the relation-
ship between an HbA1c <6.5 % and hyperfiltration.
Previous studies have indicated that patients with predia-
betes (based on impaired fasting glucose [IFG], impaired
glucose tolerance [IGT] or HbA1c of 5.7–6.4 %) are at high
risk of future T2DM and have impaired endothelial dia-
stolic function [10]. In addition, the IGT group showed
microalbuminuria and elevated levels of urinary albumin
excretion rate [10]. Measurement of eGFR and detection of
microalbuminuria are the main methods recommended by
the ADA, the National Kidney Foundation, and the Inter-
national Society of Nephrology for the screening of DN and
the monitoring of its progression in the clinical setting
[11–13]. However, the UK Prospective Diabetes Study
found that 51 % of patients with T2DM without albumin-
uria subsequently developed chronic renal insufficiency
[14]. Moreover, microalbuminuria does not necessarily lead
to macroalbuminuria, and in fact may regress spontan-
eously [15]. Furthermore, eGFR is a sensitive indicator of
renal hemodynamics, and may have advantages over micro-
albuminuria in the detection of DN [16, 17].
Recent studies have focused on the correlation between
HbA1c and the decrease in GFR in diabetes [18, 19]. How-
ever, glomerular hyperfiltration is a characteristic func-
tional abnormality in patients with diabetes mellitus [20],
and its presence is associated with an increased risk of
albuminuria and DN progression [21]. The correlation be-
tween fasting plasma glucose (FPG) levels and hyperfiltra-
tion has been well established in the general population
[22, 23]. However, measurement of FPG is affected by a
number of factors such as sleeping, foods consumed the
previous day, physical activity, sample handling, etc. [24].
Albeit not perfect, HbA1c levels are considered more stable
and representative of the chronic glucose levels in an indi-
vidual [25]. However, the correlation between HbA1c levels
and hyperfiltration has not been definitively established in
patients with diabetes; moreover, there is a paucity of data
examining this correlation in individuals with prediabetes.
Therefore, the present study was performed to analyze the




This cross-sectional study was part of the Huaian Diabetes
Prevention Program (ChiCTR-TRC-14005029) and was
approved by the Huaian Second Hospital Ethics Committee,
XuZhou Medical University, China. Written informed
consent was obtained from all participants in this study.
Study population
In the present study, 5431 subjects (aged 40–79 years)
attending annual routine health examinations under the
auspices of the local governments between August and
December 2014 at the health examination center of
Huaian Second Hospital, Affiliated Hospital of Xuzhou
Medical College in Huaian (Jiangsu, China) were en-
rolled. Subjects were subsequently excluded from the
analysis if any of the following criteria applied: (1) data
were missing for calculation of the eGFR (n = 358); (2)
previously diagnosed diabetes mellitus (n = 528); (3) pre-
viously diagnosed renal disease, including autoimmune
or drug-induced kidney disease, nephritis, renal fibrosis
or renal failure, or previous kidney transplant with on-
going renal dialysis (n = 146); (4) previously diagnosed
hepatic disease including fatty liver, liver cirrhosis and
autoimmune hepatitis (n = 1132); (5) peripheral artery dis-
ease (n = 108); (6) coronary heart disease (CHD) including
myocardial infarction and angina pectoris (n = 479); (7)
any malignant disease (n = 8); or (8) eGFR <60 mL/min/
1.73 m2 (n = 181). Therefore, 2491 subjects (1624 women)
were deemed eligible for the analysis.
Data collection
Demographic characteristics, lifestyle information, and
medical history were obtained by trained investigators using
a standard questionnaire. Body mass index (BMI) was cal-
culated as weight (kg) divided by height squared (m2).
Blood pressure (BP) was measured three consecutive times
(HEM-752 Fuzzy; Omron Company, Dalian, China), and
the mean value was used in the analysis. Venous blood
samples were collected between 07:00 and 09:00, after over-
night fasting, for the measurement of FPG, creatinine
(CREA), total cholesterol (TC), triglycerides (TG), low-
density lipoprotein cholesterol (LDL-c), and high-density
lipoprotein cholesterol (HDL-c). HbA1c was measured by
high performance liquid chromatography (Variant II and
D-10 Systems, Bio-Rad Laboratories Inc., Hercules, CA,
USA). All quality control criteria of the ADA were applied
for HbA1c measurement [8], and the laboratory was prop-
erly qualified.
Diabetes was defined according to the 2012 ADA criteria
[8]: FPG ≥126 mg/dl (7.0 mmol/L); or 2-h plasma glucose
in the 75-g oral glucose tolerance test (OGTT) ≥200 mg/dL
(11.1 mmol/L); and/or HbA1c ≥6.5 %. Prediabetes was also
defined according to the 2012 ADA criteria [8]: 100 mg/dL
(5.6 mmol/L) ≤ FPG ≤ 125 mg/dL (6.9 mmol/L) (IFG); or
140 mg/dL (7.8 mmol/L) ≤2-h plasma glucose in the 75-g
OGTT ≤199 mg/dL (11.0 mmol/L) (IGT); or HbA1c 5.7-
6.4 %. Normal glucose metabolism (NGM) was defined as
HbA1c <5.6 %, FPG <100 mg/dL (5.6 mmol) and 2-h
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plasma glucose in the 75-g OGTT <140 mg/dL
(7.8 mmol/L). Based on these criteria, 213 of the 2491
subjects included in the analysis were considered to have
newly diagnosed type 2 diabetes mellitus (T2NDM), 1037
were considered to have prediabetes, and 1241 were con-
sidered to have NGM.
eGFR was calculated from creatinine levels using the
CKD-EPI formula [26]. Normal eGFR was defined as
≥90 mL/min/1.73 m2; renal hyperfiltration as an absolute
GFR >102 mL/min/1.73 m2 (90th percentile in all subjects);
and mildly reduced eGFR as 60–90 mL/min/1.73 m2.
Statistical analysis
The continuous variables in this study exhibited normal or
approximately normal distributions, and are presented as
means ± standard deviations (SDs). Categorical variables
are presented as numbers (%). Comparisons between
groups were made using the Student’s t test for continuous
data and the chi-square test for categorical data.
After verifying the assumption of a linear relation-
ship between the dependent and independent variables
that were introduced into a linear regression model
(assessed using a histogram of the residuals, together
with a scatter plot of the standardized residuals to the
standardized predicted values in different models, as
described below), multivariate linear regression ana-
lysis was used to estimate the association of glucose
metabolism type with eGFR. Identification of patients
with hyperfiltration was done by selecting all partici-
pants >90th percentile in the distribution of residuals
from a multivariate linear regression analysis where we
used absolute GFR values as the dependent variable
and sex, age, weight, height, and use of ACE inhibitors
or ARB as the independent adjusting variables. Then,
249 subjects (147 women) were defined as being with
hyperfiltration, for a mean GFR of 102.27 (range 90.7–
135.7) mL/min/1.73 m2.
Three models were constructed for each component
of glucose metabolism. The first model was not ad-
justed. The second model was adjusted for age, gender,
waistline, BMI, systolic blood pressure, and diastolic
blood pressure. The third model was adjusted for age,
gender, waistline, BMI, systolic BP, diastolic BP, choles-
terol, log(triglyceride), HDL-c, LDL-c, serum uric acid,
alcohol consumption, smoking status, sodium intake
(6 g/day), the presence of hypertension (%), and the use
of angiotensin converting enzyme inhibitors (ACEIs) or
angiotensin receptor blockers (ARBs).
For analysis, the subjects were divided into five groups
based on stratification of glucose metabolism levels using
the 50th, 75th, 90th and 95th percentiles as cut-off points.
For HbA1c, the groups were: Q1, HbA1c <5.70 %; Q2,
HbA1c 5.70–6.00 %; Q3, HbA1c 6.01–6.20 %; Q4, HbA1c
6.21–6.49 %; and Q5, HbA1c ≥6.5 %. For FPG, the groups
were: Q1, FPG <5.40 mmol/L; Q2, FPG 5.40–5.70 mmol/L;
Q3, FPG 5.71–6.30 mmol/L; Q4, FPG 6.31–6.99 mmol/L;
and Q5, FPG ≥7.0 mmol/L). The associations of glucose
metabolism (with FPG and HbA1c quintiles introduced as
dummy ordinal independent variables) with the odds of
hyperfiltration (as defined above) were estimated using
multivariate logistic regression analysis in the same three
models described above. P-values for the trends were calcu-
lated by Spearman correlation analysis of categorical vari-
ables and odds ratios (ORs) for the different groups, scored
0, 1, 2 and 3, respectively. P < 0.05 was considered statisti-
cally significant. All statistical analyses were performed
using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the study participants
The 2491 subjects (1624 women) included in the study
were divided into three groups (NGM, prediabetes,
and T2NDM). As shown in Table 1, age, BMI, FPG,
HbA1c, TC, TG, LDL-c, SUA, alcohol consumption,
sodium intake (>6 g/day), and the proportion of sub-
jects with hypertension were significantly higher in the
prediabetes and T2NDM groups than in the NGM
group (P < 0.05), while HDL-c levels were significantly
lower (P = 0.003). Interestingly, eGFR and the proportion
of subjects with hyperfiltration were lower in the prediabe-
tes group but higher in the T2NDM group. There was no
significant difference between the three groups in systolic
BP (SBP), diastolic BP (DBP), blood urea nitrogen (BUN),
CREA, gender, and smoking status.
Among all subjects, 249 subjects (147 women) were
defined as being with hyperfiltration, for a mean GFR of
102.27 (range 90.7–135.7) mL/min/1.73 m2.
Multiple linear regression analysis
As presented in Table 2, an approximately linear rela-
tionship was found, particularly in models 2 and 3. In
model 1, the HbA1c and FPG levels were independently
negatively related to eGFR. However, after adjustment
for age, gender, waistline, BMI, SBP, DBP, cholesterol,
log(triglyceride), LDL-c, HDL-c, alcohol consumption,
smoking status, hypertension, and the use of ACEIs or
ARBs in models 2 and 3, HbA1c and FPG levels were
found to be positively related to eGFR in participants
with prediabetes and those with T2NDM.
Multiple logistic regression analysis
As shown in Table 3, the association between increased
HbA1c levels and increased odds of hyperfiltration was an-
alyzed in the three models. In model 1, both the HbA1c
and FPG levels were negatively related to GFR, but after ad-
justment for age, gender, waistline, BMI, SBP and DBP
(model 2) or age, gender, waistline, BMI, SBP, DBP, TC,
log(triglyceride), LDL-c, HDL-c, alcohol consumption,
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smoking status, hypertension, and the use of ACEIs or
ARBs (model 3), HbA1c and FPG levels showed a positive
linear relationship with an increased odds of hyperfiltration,
with the highest quintile groups (FPG ≥7.0 mmol/L
[126 mg/dL] and HbA1c ≥6.5 %) showing significantly
increased odds. In model 3 (after multivariate adjustment),
the OR (95 % CI) for hyperfiltration (relative to quintile Q1,
HbA1c <5.7 %) was 2.344 (1.025–5.364) in subjects with
HbA1c levels of 6.21–6.49 % (Q4), and 2.965 (1.537–5.720)
in those with HbA1c levels >6.5 % (Q5) (both P < 0.05).
Table 2 Multiple linear regression analysis of the relationship between HbA1c and eGFR
Fasting plasma glucose (per mmol/L) HbA1c (per % unit)
b Coefficient 95 % CI P value b Coefficient 95 % CI P value
Model 1 −0.466 (−1.037, −0.087) 0.015 −0.471 (−1.363, 0.078) 0.203
Model 2 0.424 (−0.016, 0.864) 0.059 1.044 (0.378, 1.711) 0.002
Model 3 0.761 (0.340, 1.180) <0.001 1.259 (0.625, 1.892) <0.001
Model 1: not adjusted; Model 2: adjusted for age, gender, waistline, body mass index, systolic blood pressure and diastolic blood pressure; Model 3: Model 2 plus adjustment
for cholesterol, Log (triglyceride), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum uric acid, alcohol consumption, smoking status, sodium
intake (6 g/day), hypertension, and use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers. 95 % CI, 95 % confidence interval; eGFR, estimated
glomerular filtration rate; HbA1c, glycated hemoglobin
Table 1 Characteristics of the study participants
NGM (n = 1241) Prediabetes (n = 1037) T2NDM (n = 213) P value
Male (%) 34.6 34.0 39.0 0.386
Age (years) 59.36 ± 7.39 61.04 ± 7.43 63.08 ± 7.34 <0.001
Smoking (%) 16.3 17.7 18.8 0.577
Consumption of alcohol (%) 15.4 14.9 17.9 0.033
Excess sodium intake (>6 g/d) (%) 14.4 15.7 20.7 <0.001
Hypertension (%) 39.7 43.5 47.9 0.033
Use of ACEIs or ARBs (%) 5.3 4.4 3.7 0.514
Waistline (cm) 82.26 ± 8.88 83.14 ± 9.31 85.43 ± 11.97 <0.001
BMI (kg/m2) 23.90 ± 2.96 24.32 ± 3.21 25.00 ± 3.82 <0.001
SBP (mmHg) 140.46 ± 20.11 140.42 ± 38.31 140.86 ± 20.30 0.597
DBP (mmHg) 84.75 ± 13.94 84.31 ± 14.41 83.05 ± 15.73 0.573
TC (mmol/L) 5.12 ± 0.85 5.25 ± 0.85 5.33 ± 0.91 <0.001
TG (mmol/L) 1.61 (0.5, 12.7) 1.67 (0.3, 18.1) 1.85 (0.8, 19.8) <0.001
HDL-c (mmol/L) 1.45 ± 0.61 1.39 ± 0.47 1.36 ± 0.56 0.003
LDL-c (mmol/L) 2.68 ± 0.68 2.80 ± 0.70 2.88 ± 0.75 <0.001
SUA (mg/dL) 4.76 ± 1.22 4.80 ± 1.33 4.90 ± 1.39 0.018
BUN (mmol/L) 5.18 ± 1.29 5.10 ± 1.25 5.02 ± 1.33 0.076
CREA (mmol/L) 0.78 ± 0.15 0.79 ± 0.15 0.78 ± 0.16 0.650
eGFR (mL/min per 1.73 m2) 89.39 ± 11.76 88.31 ± 11.65 88.76 ± 12.83 0.048
eGFR stage 0.013
>102 (%) 13.7 9.5 14.1
90-102 (%) 39.2 39.4 39.4
60-90 (%) 47.1 50.2 46.5
HbA1c (%) 5.32 ± 0.27 5.92 ± 0.18 7.13 ± 1.05 <0.001
FPG (mg/dL) 94.86 ± 10.08 98.18 ± 9.23 131.76 ± 15.30 <0.001
Data are presented as the mean ± SD, number (as %), or median (range), as appropriate. Comparisons between the three groups were made using ANOVA or
Fisher’s exact test, as appropriate
International system of units (SI) conversion: plasma glucose, 1 mg/dL = 1/18 mmol/L; serum uric acid, 1 mg/dL = 59.5 mmol/L; serum
creatinine, 1 mg/dL = 88.41 μmol/L
ACEI angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; BMI body mass index; BUN blood urea nitrogen; CREA serum creatinine; DBP
diastolic blood pressure; e-GFR estimated glomerular filtration rate; FPG fasting plasma glucose; HDL-c high-density lipoprotein cholesterol; LDL-c low-density
lipoprotein cholesterol; T2NDM newly diagnosed type 2 diabetes mellitus; NGM normal glucose metabolism; SBP systolic blood pressure; SUA serum uric acid;
TC total cholesterol; TG triglycerides
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Discussion
The present study has found that in a Chinese middle-
aged and elderly population without a history of dia-
betes, HbA1c was positively associated with hyperfiltra-
tion independently of age, sex, BMI, waistline, BP,
smoking status, alcohol consumption, hypertension sta-
tus, and TC, TG, LDL-c and HDL-c levels. A similar as-
sociation was found between FPG and hyperfiltration.
However, since the two conditions often coexist, the re-
sults do not exclude the association of both acutely and
chronically elevated glucose levels with eGFR, but can-
not confirm an independent association. Furthermore,
after multivariate adjustment, it was determined that the
odds of hyperfiltration were significantly increased in pa-
tients with HbA1c ≥6.21 % and FPG ≥7.0 mmol/L. Sub-
jects with HbA1c levels of 6.21–6.49 % had a 2.34-times
higher odds of developing hyperfiltration than those with
HbA1c <5.7 %. This suggests that hyperfiltration oc-
curs not only in newly developed diabetes but also in
prediabetes. Thus, more attention should be paid to
subjects with HbA1c levels ≥6.21 % in order to
maximize the prevention of hyperfiltration in patients
without overt diabetes.
Some studies, but not all, have shown an association
between hyperfiltration and the subsequent development
of nephropathy in subjects with diabetes [27]. It is
important to clarify the relationship between blood glu-
cose and hyperfiltration to allow the early diagnosis of
renal damage. GFR is increased significantly in dogs by a
continuous glucose infusion for 6 days, which produces
a modest rise in serum glucose from 6.5 to 7.1 mmol/L
[28]. Consistent with the present study, experimental
studies in healthy subjects have shown that GFR is in-
creased by an acute glucose infusion (plasma glucose to
7.0 mmol/L) [29]. Recent research into hyperfiltration
has focused on the relationship between an acute blood
glucose rise and eGFR, rather than the effects of a
chronic elevation in blood glucose level. A previous
study of 1560 Norwegians, aged 50–62 years, without
diabetes, has assessed the association between elevated
HbA1c levels and GFR [22]. In the Norwegian investiga-
tion, elevated HbA1c and borderline hyperglycemia
(FPG >5.6 mmol/L) were found to be associated with
hyperfiltration; however, the cut-off for FPG differed
from that used in the present study, and they analyzed
HbA1c as a continuous variable. Consistent with our
findings, Okada et al. found that hyperfiltration was as-
sociated with HbA1c levels in a cohort of Japanese sub-
jects with prediabetes [30]. In addition, Hou et al. have
reported that greater fluctuations between FPG and 2-h
postload glucose were associated with higher odds of
hyperfiltration [31].
Table 3 Multiple logistic regression analyses of odds ratios for hyperfiltration
Fasting plasma glucose (per mmol/L) HbA1c (per % unit)
OR 95 % CI P value OR 95 % CI P value
Model 1 Fasting glucose, per mmol/L 0.947 (0.826-1.086) 0.434 HbA1c, per % unit 0.850 (0.689-1.048) 0.128
Q1 (<5.40) 1 Q1 (<5.70) 1
Q2 (5.40-5.70) 0.654 (0.482-0.887) 0.006 Q2 (5.70-6.00) 0.644 (0.443-0.936) 0.021
Q3 (5.71-6.30) 0.786 (0.499-0.919) 0.012 Q3 (6.01-6.20) 0.593 (0.405-0.870) 0.007
Q4 (6.31-6.99) 0.692 (0.338-0.994) 0.047 Q4 (6.21-6.49) 1.234 (0.992-2.719) 0.053
Q5 (≥7.0) 0.871 (0.689-1.698) 0.734 Q5 (≥6.5) 0.900 (0.583-1.390) 0.819
Model 2 Fasting glucose, per mmol/L 1.222 (1.064-1.405) 0.005 HbA1c, per % unit 1.301 (1.027-1.648) 0.029
Q1 (<5.40) 1 Q1 (<5.70) 1
Q2 (5.40-5.70) 0.820 (0.545-1.234) 0.341 Q2 (5.70-6.00) 0.779 (0.522-1.222) 0.300
Q3 (5.71-6.30) 0.884 (0.572-1.367) 0.579 Q3 (6.01-6.20) 0.876 (0.564-1.361) 0.557
Q4 (6.31-6.99) 1.181 (0.545-1.2.563) 0.673 Q4 (6.21-6.49) 2.497 (1.144-5.440) 0.025
Q5 (≥7.0) 3.719 (1.969-7.024) <0.001 Q5 (≥6.5) 2.424 (1.315-4.469) 0.005
Model 3 Fasting glucose, per mmol/L 1.306 (1.117-1.526) 0.001 HbA1c, per % unit 1.396 (1.089-1.790) 0.008
Q1 (<5.40) 1 Q1 (<5.70) 1
Q2 (5.40-5.70) 0.845 (0.547-1.305) 0.448 Q2 (5.70-6.00) 0.968 (0.623-1.504) 0.885
Q3 (5.71-6.30) 1.144 (0.731-1.791) 0.557 Q3 (6.01-6.20) 0.945 (0.598-1.496) 0.811
Q4 (6.31-6.99) 2.369 (1.255-4.473) 0.097 Q4 (6.21-6.49) 2.344 (1.025-5.364) 0.044
Q5 (≥7.0) 4.889 (2.454-9.739) <0.001 Q5 (≥6.5) 2.965 (1.537-5.720) <0.001
Model 1: not adjusted; Model 2: adjusted for age, gender, waistline, body mass index, systolic blood pressure and diastolic blood pressure; Model 3: Model 2 plus adjustment
for cholesterol, Log (triglyceride), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum uric acid, alcohol consumption, smoking status, sodium,
hypertension, and use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers. 95 % CI, 95 % confidence interval; HbA1c, glycated
hemoglobin; OR, odds ratio
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The present study differs from previous investigations of
hyperfiltration [29, 22, 32]. First, subjects for this cross-
sectional study were selected from a Chinese population
free of CHD, diabetes, peripheral arterial disease, or chronic
kidney disease, which shows a lower GFR and lower rate of
GFR decrease than Western populations. Second, the defin-
ition of hyperfiltration that was used differed from that of
previous studies [33, 34]. The clinical relevance of hyperfil-
tration is based on a proposed pathological effect of in-
creased single nephron GFR, which cannot be measured in
humans. Therefore, we selected an absolute GFR above the
90th percentile as the definition of hyperfiltration, rather
than an arbitrary threshold that has ranged in various stud-
ies from 125 to 140 mL/min/1.73 m2. Third, extensive co-
variate data, including age, gender, BMI, cigarette smoking
status, alcohol consumption, sodium intake, hypertension
history, SBP, DBP, log(TG), TC, HDL-c, LDL-c, FPG, SUA,
eGFR, and waistline were used in the statistical analysis.
The present study is supported by two previous ones
[22, 30], but these two studies were performed in differ-
ent populations and using different definitions of hyper-
glycemia and high HbA1c levels. In addition, they
mainly focused on FPG, which are biased by a number
of factors [24]. Taken together, these results may help
clinicians to intervene earlier to prevent kidney damage
due to hyperfiltration.
Creatinine-based equations for estimating GFR include
the Cockcroft-Gault equation proposed in 1976 [35], the
Modification of Diet in Renal Disease (MDRD) study equa-
tion proposed in 1999 [36], and the CKD-EPI equation pro-
posed in 2009 [15]. The Cockcroft-Gault equation has now
been supplanted by the MDRD study equation and the
CKD-EPI equation [37]. A recent study performed in South
Asians, aged 40 years or older (as in the present study)
demonstrated that the CKD-EPI equation was more accur-
ate and precise in estimating GFR than the MDRD study
equation [38]. Therefore, the CKD-EPI equation was se-
lected for the calculation of eGFR in the present study.
The etiology of increased GFR in the setting of elevated
blood glucose and HbA1c is incompletely understood, but
has been attributed to the effect of hyperglycemia on the
renin-angiotensin-aldosterone system (RAAS). Miller et al.
demonstrated that hyperfiltration responses to clamped
hyperglycemia are related to intrarenal RAAS activation
[39]. Moreover, proximal sodium reabsorption is higher in
individuals with IFG than in subjects with normal FPG
[32]. To the best of our knowledge, there is no current evi-
dence for a direct effect of glucose on creatinine, suggesting
that the positive relationship between blood glucose and
eGFR is likely reflective of changes in GFR.
Of course, the present study has some limitations. First,
the study sample might not be completely representative of
the general population. Second, the methods used to meas-
ure eGFR may be influenced by non-GFR factors such as
body composition and glycemic status [38], and by non-
traditional factors such as asymmetric dimethylarginine
(ADMA), symmetric dimethylarginine, L-arginine/ADMA
ratio, and insulin resistance [40]. In addition, the mean
eGFR of the Chinese subjects in our study was lower than
that of Western populations [29, 22, 32], which may be due
to a number of lifestyle and genetic factors. Third, a cross-
sectional study cannot infer causality between HbA1c,
hyperfiltration, and nephropathy. Therefore, longitu-
dinal studies are needed to investigate whether the
hyperfiltration associated with increased HbA1c is a risk
factor for renal injury in the general population. Fourth,
this study did not include consideration of insulin re-
sistance, a factor that some have suggested may affect
hyperfiltration [22, 41], but which is still controversial
[42]. Finally, prediabetes was defined based on FPG and
HbA1c only; OGTT was not performed, and it is pos-
sible that some patients may have been missed [43].
Conclusions
Elevated HbA1c levels are associated with increased
odds of hyperfiltration in a middle-aged and elderly
Chinese population. It is possible that hyperfiltration
associated with elevated HbA1c (≥6.21 %) may be one
of several mechanisms that cause renal injury in this
population of patients.
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